Retro Biosciences Seeks $1B to Reverse Aging

Retro Biosciences, a deep-tech startup backed significantly by Sam Altman, is reportedly seeking to raise approximately $1 billion in new funding. The company, which aims to fundamentally reverse the aging process and extend human lifespan, is operating with a $5 billion valuation. This ambitious funding round, coordinated by Sandro Salsano of a Panama-based family office, signals a major push to advance its pipeline of novel therapies.

The core scientific premise of Retro Biosciences revolves around rejuvenating the body at a cellular level. Instead of treating age-related diseases individually, the company's strategy focuses on addressing the root cause: cellular senescence and epigenetic dysregulation. By employing techniques such as epigenetic editing and cellular replacement, Retro intends to restore youthful function to deteriorating tissues. This approach positions the company to potentially disrupt the multi-trillion dollar global healthcare market, where a significant portion of spending is dedicated to conditions exacerbated by aging.

A key development in Retro's pipeline is the experimental drug RTR242, designed to combat Alzheimer's disease. This therapy aims to reactivate cellular autophagy, the body's natural recycling process that often falters with age. Beyond Alzheimer's, the company's research portfolio spans approximately 20 potential treatments targeting conditions like blood disorders, hearing loss, and various degenerative diseases. This broad scope underscores the company's expansive vision for age-reversal therapies.

The substantial backing from Sam Altman, co-founder and CEO of OpenAI, has been instrumental in Retro's early development. In 2023, Altman reportedly invested a significant portion of his personal wealth, estimated at $180 million, into the venture. Recent legal filings have further highlighted the value of his stake, placing it at approximately $258 million. This deep commitment from a prominent tech investor underscores the perceived potential of Retro's groundbreaking mission.

Retro Biosciences projects that its success could dwarf established pharmaceutical giants. Pitch materials suggest the company envisions surpassing the market capitalizations of industry leaders like Eli Lilly and Novo Nordisk, and potentially reaching the scale of major technology firms such as Microsoft and Alphabet. This bold projection is rooted in the belief that longevity will emerge as the largest pharmaceutical market ever, given that roughly 90% of U.S. healthcare expenditures are linked to age-related ailments, a figure exceeding $3 trillion annually.

Founded five years ago by a trio of scientific and entrepreneurial minds—CEO Joe Betts-LaCroix, stem cell expert Sheng Ding, and aging process specialist Matt Buckley—Retro Biosciences is also leveraging artificial intelligence. The company has a collaborative project with OpenAI to develop a specialized AI model for protein engineering. This synergy between advanced biology and AI is central to accelerating the development of its complex therapeutic candidates.

While Retro's therapies are still in preclinical stages, the company's ambitious goals and significant early investment have captured considerable attention. The current funding round aims to propel its diverse research programs toward clinical trials, a critical step in validating its revolutionary approach to human health and longevity. The success of this funding effort will be closely watched as a bellwether for the burgeoning longevity sector.